Skip Navigation

Annals of Oncology 2004 15(12):1848; doi:10.1093/annonc/mdh479
This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow E-letters: Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when E-letters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Search for citing articles in:
ISI Web of Science (1)
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Singh, D.
Right arrow Articles by Sekhon, J. S.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Singh, D.
Right arrow Articles by Sekhon, J. S.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© 2004 European Society for Medical Oncology

Symptomatic hypocalcaemia after treatment with zoledronic acid in a patient with multiple myeloma

The first 10% of the full text of this article appears below.

Zoledronic acid is a long-acting bisphosphonate used to decrease skeletal events in patients with multiple myeloma and bony metastasis. It is known to lead to asymptomatic hypocalcaemia, but symptomatic hypocalcaemia after its use is rarely reported [1Go]. . . . [Full Text of this Article]

D. Singh*, N. S. Khaira and J. S. Sekhon

Dayanand Medical College and Hospital, Ludhiana Punjab, India 141 001

* Email: devinderaiims@hotmail.com


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 Ann OncolHome page
T. Tanvetyanon and P. J. Stiff
Management of the adverse effects associated with intravenous bisphosphonates
Ann. Onc., June 1, 2006; 17(6): 897 - 907.
[Abstract] [Full Text] [PDF]